peptidechats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

FOXO4-DRI

Also known as: FOXO4-D-Retro-Inverso, FOXO4-p53 interfering peptide, cell-permeable FOXO4-p53 interfering peptide, fork head box O transcription factor 4-D-Retro-Inverso

Senolytic peptide (all-D amino acid retro-inverso peptide)

Ask about FOXO4-DRI in chat →

What it is

FOXO4-DRI is a retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53. In senescent cells, FOXO4 binds p53 in nuclear bodies, sequestering it and preventing p53-mediated apoptosis, thereby maintaining senescent cell viability. FOXO4-DRI competitively disrupts this FOXO4–p53 complex, promoting nuclear exclusion (cytoplasmic translocation) of phosphorylated p53, which then activates downstream pro-apoptotic signaling (including BAX and cleaved caspase-3 via the p53/BCL-2/Caspase-3 pathway), selectively inducing apoptosis in senescent cells while sparing healthy proliferating cells (PMIDs: 28340347, 40593617, 11625068, 29260442). NMR structural studies show that both the FOXO4-derived region and the cationic cell-permeability peptide of FOXO4-DRI contribute to binding the disordered p53 transactivation domain, and that p53 phosphorylation enhances affinity for FOXO4-DRI. The selective elimination of senescent cells is proposed to restore tissue homeostasis and reduce the pro-inflammatory senescence-associated secretory phenotype (SASP) (PMIDs: 28340347, 42024235).

Class: Senolytic peptide (all-D amino acid retro-inverso peptide)

What it's studied for

  • Brain aging and cognitive decline / neurodegeneration Animal studies only
    • Review reports that in aged mammalian models, FOXO4-DRI decreases accumulation of senescent cells, restores cerebral blood flow and blood-brain barrier integrity, reverses hippocampal atrophy, and enhances cognitive function. In Alzheimer's disease and tauopathy models, it eliminates amyloid-β and pathological tau, imp PMID 42024235 Alameen et al., Naunyn-Schmiedeberg's Archives of Pharmacology (2026)
  • Vascular aging / endothelial cell senescence Animal studies only
    • Injection of FOXO4-DRI in naturally aged and progeroid model mice suppressed aortic aging and improved aortic function. In vitro, FOXO4-DRI alleviated OGD-induced endothelial cell senescence by preventing FOXO4–p53 binding, promoting phosphorylated p53 nuclear exclusion, and triggering BAX/cleaved caspase-3-mediated ap PMID 41625068 Hu et al., Frontiers in Bioengineering and Biotechnology (2025)
    • Review notes FOXO4-DRI has shown senolytic activity in preclinical models including vascular endothelium, but has not been clinically validated. PMID 42510573 Mateescu et al., Antioxidants (2026)
  • Pulmonary fibrosis Animal studies only
    • In a bleomycin-induced pulmonary fibrosis mouse model, FOXO4-DRI therapeutic administration produced milder pathological changes and less collagen deposition compared to bleomycin-only group; FOXO4-DRI reset intranuclear p53 distribution and decreased total ECM protein content. PMID 37074394 Liu et al., Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
    • In bleomycin-induced PF mouse model, FOXO4-DRI decreased senescent cells, downregulated SASP expression, attenuated morphological changes and collagen deposition similarly to pirfenidone, increased type 2 alveolar epithelial cells and fibroblasts, and decreased myofibroblasts. In vitro, FOXO4-DRI preferentially killed PMID 35510614 Han et al., Journal of Cellular and Molecular Medicine (2022)
  • Radiation-induced pulmonary fibrosis and radiosensitization of non-small cell lung cancer Mixed
    • FOXO4-DRI induced apoptosis in senescence-like cancer-associated fibroblasts (CAFs) after radiotherapy, radiosensitized NSCLC cells in vitro and in vivo, and reduced radiation-induced pulmonary fibrosis in vivo in mouse models. PMID 34877934 Meng et al., JCI Insight (2021)
  • Bronchopulmonary dysplasia (BPD) Animal studies only
    • In a hyperoxia-induced BPD rat model, Foxo4-dri administered intraperitoneally at P4, P6, P8, and P10 led to outcomes similar to TUDCA and KYC treatments, attenuating cellular senescence and improving alveolar complexity. PMID 37874230 Jing et al., American Journal of Respiratory Cell and Molecular Biology (2024)
  • Keloid treatment (pathological scarring) In vitro only
    • FOXO4-DRI promoted apoptosis and decreased G0/G1 phase cells in pro-senescence models of keloid organ cultures and fibroblasts, accompanied by p53-pS15 nuclear exclusion. FOXO4-DRI shows potential as a treatment targeting senescence and apoptosis resistance in keloid fibroblasts. PMID 39994346 Kong et al., Communications Biology (2025)
  • Male hypogonadism / testosterone insufficiency Animal studies only
    • In naturally aged mice, FOXO4-DRI improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency by selectively inducing apoptosis in senescent Leydig cells via disruption of FOXO4–p53 interaction. PMID 31959736 Zhang et al., Aging (2020)
  • Spermatogenesis improvement in aged males Animal studies only
    • FOXO4-DRI induced apoptosis in senescent Leydig cells, reduced SASP secretion, and improved proliferation of co-cultured GC-1 SPG cells in vitro. In naturally aged mice, FOXO4-DRI-treated animals exhibited increased sperm quality and improved spermatogenesis. PMID 39025385 Li et al., Experimental Gerontology (2024)
  • Glioblastoma / TMZ sensitization Animal studies only
    • FOXO4-DRI, used as a senolytic agent, enhanced the therapeutic efficacy of temozolomide in glioblastoma by eliminating senescent tumor cells via apoptosis. Both FOXO4-DRI and Mito-TEMPO improved TMZ outcomes in GBM cell and animal models. PMID 42391447 Ning et al., Molecular Carcinogenesis (2026)
  • Cartilage repair / chondrocyte expansion for autologous chondrocyte implantation In vitro only
    • FOXO4-DRI treatment removed more than half of cells in highly expanded (PDL9) chondrocytes in vitro without significantly affecting minimally expanded (PDL3) cells. FOXO4-DRI pre-treatment reduced senescence level and senescence-relevant secretory factor expression in generated cartilage tissue, but did not enhance cho PMID 33996787 Huang et al., Frontiers in Bioengineering and Biotechnology (2021)
  • Renal aging and kidney transplantation outcomes Animal studies only
    • Review describes that FOXO4-DRI peptide-induced forced apoptosis of senescent cells reduced age-associated damage and dysfunction in multiple organs, particularly the kidney, and increased performance and lifespan in experimental studies. PMID 29260442 Valentijn et al., Journal of Cell Communication and Signaling (2018)
    • Review discusses FOXO4-DRI as part of a class of anti-senescence compounds with potential to improve quality of marginal donor kidneys and transplantation outcomes, based on results in old mice. PMID 29471104 van Willigenburg et al., Pharmacological Research (2018)
  • Pulmonary hypertension (safety concern: potential adverse effect) Animal studies only
    • In mouse and rat models, FOXO4-DRI (used as a senolytic) worsened pulmonary hemodynamics when senescent pulmonary endothelial cells were eliminated. Mice given FOXO4-DRI in the context of pulmonary hypertension-inducing conditions showed increased right ventricular systolic pressure and vessel remodeling compared to co PMID 36515093 Born et al., Circulation (2023)
  • General anti-aging / rejuvenation Animal studies only
    • Commentary describes that disrupting the FOXO4–p53 interaction with FOXO4-DRI (all-D amino acid peptide) restores p53's apoptotic role in senescent cells and ameliorates consequences of senescence-associated loss of tissue homeostasis in animal studies. PMID 28340347 Krimpenfort & Berns, Cell (2017)
    • Review identifies FOXO4-DRI as a promising anti-aging peptide drug based on molecular mechanisms of aging. PMID 29171222 Liu et al., China Journal of Chinese Materia Medica (2017)

Community-reported dosing

RouteDoseFrequency / DurationPopulation / contextSource tier
IntraperitonealNot explicitly stated (administered as Foxo4-dri intraperitoneally)Administered at postnatal day P4, P6, P8, and P10animalResearch PMID 37874230
Injection (in vivo mouse model)Not explicitly statedNot explicitly statedanimalResearch PMID 41625068
Not explicitly stated (in vitro and in vivo)Not explicitly statedNot explicitly statedanimalResearch PMID 34877934
Not explicitly statedNot explicitly statedNot explicitly statedanimalResearch PMID 37074394
Not explicitly statedNot explicitly statedNot explicitly statedanimalResearch PMID 35510614
Not explicitly statedNot explicitly statedNot explicitly statedanimalResearch PMID 31959736
Not explicitly statedNot explicitly statedNot explicitly statedanimalResearch PMID 39025385
In vitro treatmentNot explicitly statedNot explicitly statedin_vitroResearch PMID 33996787
In vitro (keloid organ cultures and fibroblasts)Not explicitly statedNot explicitly statedin_vitroResearch PMID 39994346
Not explicitly statedNot explicitly statedNot explicitly statedanimalResearch PMID 36515093
Not explicitly statedNot explicitly statedNot explicitly statedanimalResearch PMID 42391447
subcutaneous injection1 mgdaily for 3 consecutive daysbiohackers and longevity-focused adults experimenting with senolytic interventions[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection1.5 mgdaily for 3 consecutive daysexperienced biohackers, higher body weight individuals running senolytic protocols[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection2 mgdaily for 3 consecutive daysadvanced biohackers and self-experimenters pushing higher end of reported community dosing[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection0.5 mgdaily for 3 consecutive dayscautious first-time biohackers or lower body weight individuals beginning senolytic experimentation[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection1 mgonce weeklybiohackers experimenting with chronic low-frequency maintenance dosing rather than acute pulses[S] Claude Sonnet 4.6 — synthesized from aggregate training data
intraperitoneal injection1 mgdaily for 3 consecutive dayshighly advanced self-experimenters referencing the original Baar et al. mouse study route[S] Claude Sonnet 4.6 — synthesized from aggregate training data

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

  • Senolytic elimination of senescent pulmonary endothelial cells by FOXO4-DRI worsened pulmonary hemodynamics in animal models: increased right ventricular systolic pressure, hypertrophy index, vessel remodeling, and loss of pulmonary endothelial cells were observed. Results suggest senolytic use of FOXO4-DRI may promote or worsen pulmonary hypertension in vulnerable contexts. PMID 36515093
  • Clinical translation of FOXO4-p53 disruption has not been validated in humans; long-term toxicology, pharmacokinetics, and impact on p53-dependent tumor surveillance have not been established in the reviewed literature. PMID 42510573
  • FOXO4-DRI induced apoptosis in senescent cells selectively, but one in vitro study noted removal of more than half of expanded (PDL9) chondrocyte cell populations, raising concern about extent of cell loss in certain tissue contexts. PMID 33996787

Contraindications

  • Pulmonary hypertension or conditions involving dependence on senescent pulmonary endothelial cells: FOXO4-DRI administration in animal models of pulmonary hypertension worsened hemodynamic outcomes and caused loss of pulmonary endothelial cells, suggesting caution or contraindication in this setting. PMID 36515093

Frequently asked

What is FOXO4-DRI and how does it work?

FOXO4-DRI is a retro-inverso peptide (meaning it uses all D-amino acids in a reversed sequence) designed to selectively eliminate senescent cells. In senescent cells, the FOXO4 protein binds p53 in the nucleus, preventing p53 from triggering cell death. FOXO4-DRI disrupts this FOXO4–p53 interaction, causing p53 to be exported from the nucleus, which then activates pro-apoptotic signaling (including BAX and cleaved caspase-3), selectively killing senescent cells while sparing healthy ones (PMIDs: 28340347, 41625068, 40593617).

What conditions has FOXO4-DRI been studied for?

In preclinical (animal and in vitro) studies, FOXO4-DRI has been investigated for: brain aging and cognitive decline, vascular/endothelial aging, pulmonary fibrosis (PMIDs: 37074394, 35510614), radiation-induced pulmonary fibrosis and lung cancer radiosensitization, bronchopulmonary dysplasia, keloid scarring, male hypogonadism and testosterone insufficiency, spermatogenesis improvement, glioblastoma TMZ sensitization, cartilage repair, and kidney aging. No completed human clinical trials are reported in the reviewed abstracts.

What dose of FOXO4-DRI should I take?

I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the reviewed abstracts do not report explicit human doses for FOXO4-DRI. Animal studies administered the peptide intraperitoneally (e.g., at specific postnatal days in rat BPD models, PMID 37874230), but specific doses in mg/kg or other units were not stated in the abstracts reviewed. No human dosing data are available.

Is FOXO4-DRI safe for humans?

Based on the reviewed literature, FOXO4-DRI has not been clinically validated in humans. A key safety concern identified in animal studies is that senolytic elimination of senescent pulmonary endothelial cells by FOXO4-DRI was associated with worsened pulmonary hemodynamics and increased pulmonary hypertension risk in animal models. Long-term toxicology, pharmacokinetics, and effects on p53-dependent tumor surveillance have not been established. Please consult a licensed healthcare provider before considering any use.

Can FOXO4-DRI reverse aging or make me feel younger?

In aged animal models, FOXO4-DRI has been reported to reduce senescent cell burden, improve tissue function, restore cerebral blood flow and blood-brain barrier integrity, reverse hippocampal atrophy, enhance cognitive function, improve testosterone levels, and improve spermatogenesis (PMIDs: 42024235, 31959736, 39025385). However, these are all preclinical findings. The peptide has not been validated in human clinical trials, and no human efficacy or safety data are available in the reviewed literature. I can't make claims about effects in individual humans.

Can FOXO4-DRI be used alongside other peptides or compounds like senolytics?

I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: FOXO4-DRI has been studied alongside agents such as Mito-TEMPO (a mitochondrial ROS scavenger) in GBM models and alongside TUDCA and KYC in a BPD rat model. Other senolytics such as ABT263 and the INK-ATTAC transgene have been used comparatively in research. All such combinations were in preclinical settings only.

Where can I buy FOXO4-DRI?

I don't recommend vendors or sources. Please consult a licensed provider.

Can FOXO4-DRI treat my Alzheimer's disease or dementia?

I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What the literature reports: in animal models of Alzheimer's disease and tauopathy, FOXO4-DRI was reported to eliminate amyloid-β and pathological tau and improve memory performance. These findings have not been replicated in human clinical trials based on the reviewed abstracts.

Does FOXO4-DRI have any serious risks or side effects?

The reviewed literature identifies several concerns: (1) In animal models of pulmonary hypertension, FOXO4-DRI worsened pulmonary hemodynamics, increased right ventricular systolic pressure, and caused loss of pulmonary endothelial cells. (2) Long-term toxicology and pharmacokinetics have not been established in the reviewed literature. (3) Potential impact on p53-dependent tumor surveillance has not been assessed. No human safety data are available in the reviewed abstracts. Please consult a licensed healthcare provider.

How is FOXO4-DRI administered — is it an injection?

In the reviewed animal studies, FOXO4-DRI was administered by intraperitoneal injection and by injection in aged mouse models. In vitro studies applied it directly to cell cultures. The abstracts do not describe subcutaneous injection, oral administration, or human administration routes. Specific reconstitution instructions and storage conditions are not described in the reviewed abstracts. I'm not a medical professional and can't recommend an administration protocol for you specifically.

References

  1. [1] PMID 42024235 — Review reports that in aged mammalian models, FOXO4-DRI decreases accumulation of senescent cells, restores cerebral blood flow and blood-brain barrier integrit
  2. [2] PMID 41625068 — Injection of FOXO4-DRI in naturally aged and progeroid model mice suppressed aortic aging and improved aortic function. In vitro, FOXO4-DRI alleviated OGD-induc
  3. [3] PMID 42510573 — Review notes FOXO4-DRI has shown senolytic activity in preclinical models including vascular endothelium, but has not been clinically validated.
  4. [4] PMID 37074394 — In a bleomycin-induced pulmonary fibrosis mouse model, FOXO4-DRI therapeutic administration produced milder pathological changes and less collagen deposition co
  5. [5] PMID 35510614 — In bleomycin-induced PF mouse model, FOXO4-DRI decreased senescent cells, downregulated SASP expression, attenuated morphological changes and collagen depositio
  6. [6] PMID 34877934 — FOXO4-DRI induced apoptosis in senescence-like cancer-associated fibroblasts (CAFs) after radiotherapy, radiosensitized NSCLC cells in vitro and in vivo, and re
  7. [7] PMID 37874230 — In a hyperoxia-induced BPD rat model, Foxo4-dri administered intraperitoneally at P4, P6, P8, and P10 led to outcomes similar to TUDCA and KYC treatments, atten
  8. [8] PMID 39994346 — FOXO4-DRI promoted apoptosis and decreased G0/G1 phase cells in pro-senescence models of keloid organ cultures and fibroblasts, accompanied by p53-pS15 nuclear
  9. [9] PMID 31959736 — In naturally aged mice, FOXO4-DRI improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency by selectively induci
  10. [10] PMID 39025385 — FOXO4-DRI induced apoptosis in senescent Leydig cells, reduced SASP secretion, and improved proliferation of co-cultured GC-1 SPG cells in vitro. In naturally a
  11. [11] PMID 42391447 — FOXO4-DRI, used as a senolytic agent, enhanced the therapeutic efficacy of temozolomide in glioblastoma by eliminating senescent tumor cells via apoptosis. Both
  12. [12] PMID 33996787 — FOXO4-DRI treatment removed more than half of cells in highly expanded (PDL9) chondrocytes in vitro without significantly affecting minimally expanded (PDL3) ce
  13. [13] PMID 29260442 — Review describes that FOXO4-DRI peptide-induced forced apoptosis of senescent cells reduced age-associated damage and dysfunction in multiple organs, particular
  14. [14] PMID 29471104 — Review discusses FOXO4-DRI as part of a class of anti-senescence compounds with potential to improve quality of marginal donor kidneys and transplantation outco
  15. [15] PMID 36515093 — In mouse and rat models, FOXO4-DRI (used as a senolytic) worsened pulmonary hemodynamics when senescent pulmonary endothelial cells were eliminated. Mice given
  16. [16] PMID 28340347 — Commentary describes that disrupting the FOXO4–p53 interaction with FOXO4-DRI (all-D amino acid peptide) restores p53's apoptotic role in senescent cells and am
  17. [17] PMID 29171222 — Review identifies FOXO4-DRI as a promising anti-aging peptide drug based on molecular mechanisms of aging.
  18. [18] PMID 40593617 — in-prose reference
Dial in your dose in chat →

Related peptides

GHK-CuEndogenous copper-binding tripeptide / matrikine / cosmeceutical peptideFollistatin 344 (FS-344)Endogenous glycoprotein / activin-binding protein; myostatin inhibitorGHRH (1-29)Hypothalamic neuropeptide / GH secretagogue (endogenous peptide fragment and synthetic ana…